Effect of n-3 fatty acids on patients with advanced lung cancer: A double-blind, placebo-controlled study

British Journal of Nutrition

Volumn 108, Issue 2, 2012, Pages 327-333

  Finocchiaro, Concetta ^a   Segre, Olivia ^a   Fadda, Maurizio ^a   Monge, Taira ^a   Scigliano, Mara ^a   Schena, Marina ^a   Tinivella, Marco ^b   Tiozzo, Elisa ^b   Catalano, Maria G ^c   Pugliese, Mariateresa ^c   Fortunati, Nicoletta ^a   Aragno, Manuela ^c   Muzio, Giuliana ^c   Maggiora, Marina ^c   Oraldi, Manuela ^c   Canuto, Rosa A ^c  

^a MOLINETTE HOSPITAL   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Cachexia; Inflammatory parameters; Lung tumours; N 3 Fatty acids

Indexed keywords

4 HYDROXYNONENAL; C REACTIVE PROTEIN; CISPLATIN; DOCOSAHEXAENOIC ACID; GEMCITABINE; ICOSAPENTAENOIC ACID; INTERLEUKIN 6; PLACEBO; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVANCED CANCER; AGED; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BODY WEIGHT; CALORIC INTAKE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ERYTHROCYTE; ERYTHROCYTE MEMBRANE; FATTY ACID BLOOD LEVEL; HUMAN; INFLAMMATION; LUNG NON SMALL CELL CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NUTRITIONAL STATUS; PROTEIN BLOOD LEVEL; PROTEIN INTAKE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIOXIDANTS; C-REACTIVE PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; INTERLEUKIN-6; LUNG NEOPLASMS; MALE; OXIDATIVE STRESS; PATIENT DROPOUTS; WEIGHT GAIN;

EID: 84863819822     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114511005551     Document Type: Review

References (43)

1. Ross JA, Moses AGW & Fearon KCH (1999) The anti-catabolic effect of n-3 fatty acids. Curr Opin Clin Nutr Metab Care 2, 219-226. (Pubitemid 129627821)
2. De Leiris J, De Lorgeril M & Boucher F (2009) Fish oil and heart health. J Cardiovasc Pharmacol 54, 378-384.
3. Mayer K & Seeger W (2008) Fish oil in critical illness. Curr Opin Clin Nutr Metab Care 11, 121-127. (Pubitemid 351323172)
4. Singer P & Shapiro H (2009) Enteral omega-3 in acute respiratory distress syndrome. Curr Opin Clin Nutr Metab Care 12, 123-128.
5. Holub BJ (2009) Docosahexaenoic acid (DHA) and cardiovascular disease risk factors. Prostaglandins Leukot Essent Fatty Acids 81, 199-204.
6. Friesecke S, Lotze C, Kohler J, et al. (2008) Fish oil supplementation in the parenteral nutrition of critically ill medical patients: a randomised controlled trials. Intensive Care Med 34, 1411-1420.
7. Colomer R, Moreno-Nogueira J, Garcia-Luna P, et al. (2007) n-3 fatty acids, cancer and cachexia: a systematic review on the literature. Br J Nutr 97, 823-831. (Pubitemid 46554396)
8. Evans WJ, Morley JE, Argiles J, et al. (2008) Cachexia: a new definition. Clin Nutr 27, 203-209.
9. Fearon KC, Von Meyenfeldt MF, Moses AGW, et al. (2003) Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 52, 1479-1486. (Pubitemid 37176729)
10. Bruera E, Strasser F, Palmer JL, et al. (2003) Effect of fish oil on appetite and other symptoms in patient with advanced cancer and anorexia/cachexia: a double-blind, placebocontrolled study. J Clin Oncol 21, 129-134.
11. Calder PC (2009) Polyunsatured fatty acids and inflammatory processes: new twists in an old tale. Biochimie 91, 791-795.
12. Whitehouse AS & Tisdale MJ (2003) Increased expression of the ubiquitin-proteasome pathway in murine myotubes by proteolisis-inducing factor (PIF) is associated with activation of the transcription factor NK-kB. Br J Cancer 89, 1116-1122. (Pubitemid 37239221)
13. Calder PC (2007) Immunomodulation by omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 77, 327-335. (Pubitemid 350198856)
14. Jho DH, Cole SM, Lee EM, et al. (2004) Role of omega-3 fatty acid supplementation in inflammation and malignancy. Integr Cancer Ther 3, 98-111. (Pubitemid 38669043)
15. Martin F, Santolaria F, Batista N, et al. (1999) Cytokine levels (IL-6 and INF-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 11, 80-86. (Pubitemid 29097356)
16. Simons JP, Schols AM, Buurman WA, et al. (1999) Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci (Lond) 97, 125-123.
17. Fearon KC, Barber MD, Moses AG, et al. (2006) Double-Blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 24, 3401-3407. (Pubitemid 46638896)
18. McLean CH, Newberry SJ, Mojica WA, et al. (2006) Effects of omega-3 fatty acids on cancer risk, a systematic review. JAMA 295, 403-415. (Pubitemid 43144977)
19. Dewey A, Baughan C, Dean TP, et al. (2009) Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev 24, CD004597.
20. Prior WA (1997) Cigarette smoke radicals and the role of free radicals in chemical carcinogenity. Environ Health Perspect 105, 875-882.
21. Mossman BT & Gee JB (1998) Asbestosis-related disease. N Engl J Med 320, 1721-1730.
22. Hardman WE (2002) Omega-3 fatty acids to augment cancer therapy. J Nutr 132, 3508S-3511S.
23. Burns CP, Halabi S, Clamon G, et al. (2004) Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia. Cancer 101, 370-378. (Pubitemid 38890842)
24. Larsson SC, Kumlin M, Ingelman-Sundberg M, et al. (2004) Dietary long-chain n-3 fatty acids for prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 79, 935-945. (Pubitemid 41095944)
25. Mantovani G, Macciò A, Lai P, et al. (1998) Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol 25, 45-52. (Pubitemid 28268504)
26. Weijl NI, Cleton FJ & Osanto S (1997) Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat Rev 23, 209-240. (Pubitemid 27464149)
27. Detsky AS, Smalley PS & Chang J (1994) The rational clinical examination. Is this patients malnourished? JAMA 271, 150-157.
28. Food Composition Tables (2000) National Research Institute for Food and Nutrition (INRAN). www.inran.it
29. Trombetta A, Maggiora M, Martinasso G, et al. (2007) Arachidonic and docosahexaenoic acids reduce the growth of A549 human lung-tumor cells increasing lipid peroxidation and PPARs. Chem Biol Interact 165, 239-520.
30. Ravindranath V (1994) Animal models and molecular markers for cerebral ischemia-reperfusion injury in brain. Methods Enzymol 233, 610-619.
31. Esterbauer H, Schaur RJ & Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11, 81-128. (Pubitemid 121003917)
32. Ravasco P, Monteiro-Grillo I, Marques VP, et al. (2005) Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck 27, 659-668. (Pubitemid 41113766)
33. Ross PJ, Ashley S, Norton A, et al. (2004) Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancer? Br J Cancer 90, 1905-1911. (Pubitemid 38746329)
34. Jatoi A (2005) V-3 fatty acid supplementation for cancerassociated weight loss. Nutr Clin Pract 20, 394-399. (Pubitemid 47050809)
35. Staal-van den Brekel AJ, Dentener MA, Schols AM, et al. (1995) Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol 13, 2600-2605.
36. Moses AW, Slater C, Preston T, et al. (2004) Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplementation enriched with n-3 fatty acids. Br J Cancer 90, 996-1002. (Pubitemid 38495818)
37. Brown T, Zelnik D & Dobs A (2003) Fish oil supplementation in the treatment of cachexia in pancreatic cancer patients. Int J Gastrointest Cancer 34, 143-150.
38. Guarcello M, Riso S, Buosi R, et al. (2007) EPA-enriched oral nutritional support in patients with lung cancer: effects on nutritional status and quality of life. Nutr Ther Metab 25, 25-30. (Pubitemid 351954703)
39. Elia M, Van Bokhorst-de van der Schueren MA, Garvey J, et al. (2006) Enteral (oral or tube administration) nutritional support and eicosapentanoic acid in patients with cancer: a systematic review. Int J Oncol 28, 5-23.
40. Barber MD, Ross JA, Voss AC, et al. (1999) The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 81, 80-86. (Pubitemid 29415495)
41. Barber MD, Mc Millan DC, Preston T, et al. (2000) Metabolic response to feeding in weight-losing pancreatic cancer patients and its modulation by a fish-oil-enriched nutritional supplement. Clin Sci (Lond) 98, 389-399. (Pubitemid 30197852)
42. Wigmore SJ, Barber MD, Ross JA, et al. (2000) Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer 36, 177-184. (Pubitemid 30437038)
43. Van der Meij B, Langius J, Smit E, et al. (2010) Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment. J Nutr 140, 1774-1780.